Hanall Biopharma - Asset Resilience Ratio
Hanall Biopharma (009420) has an Asset Resilience Ratio of 3.91% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 009420 current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2024)
This chart shows how Hanall Biopharma's Asset Resilience Ratio has changed over time. See Hanall Biopharma net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Hanall Biopharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 009420 stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩8.32 Billion | 3.91% |
| Total Liquid Assets | ₩8.32 Billion | 3.91% |
Asset Resilience Insights
- Limited Liquidity: Hanall Biopharma maintains only 3.91% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Hanall Biopharma Industry Peers by Asset Resilience Ratio
Compare Hanall Biopharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for Hanall Biopharma (2011–2024)
The table below shows the annual Asset Resilience Ratio data for Hanall Biopharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.91% | ₩8.32 Billion ≈ $5.64 Million |
₩212.88 Billion ≈ $144.27 Million |
-5.59pp |
| 2023-12-31 | 9.50% | ₩22.77 Billion ≈ $15.43 Million |
₩239.75 Billion ≈ $162.47 Million |
-7.88pp |
| 2022-12-31 | 17.38% | ₩37.09 Billion ≈ $25.14 Million |
₩213.45 Billion ≈ $144.65 Million |
-16.77pp |
| 2021-12-31 | 34.15% | ₩67.78 Billion ≈ $45.93 Million |
₩198.48 Billion ≈ $134.51 Million |
-5.15pp |
| 2020-12-31 | 39.30% | ₩86.51 Billion ≈ $58.62 Million |
₩220.13 Billion ≈ $149.18 Million |
-7.37pp |
| 2019-12-31 | 46.67% | ₩89.31 Billion ≈ $60.53 Million |
₩191.38 Billion ≈ $129.70 Million |
+5.59pp |
| 2018-12-31 | 41.08% | ₩66.67 Billion ≈ $45.18 Million |
₩162.30 Billion ≈ $109.99 Million |
+9.26pp |
| 2017-12-31 | 31.82% | ₩53.67 Billion ≈ $36.37 Million |
₩168.70 Billion ≈ $114.32 Million |
-4.62pp |
| 2016-12-31 | 36.43% | ₩45.44 Billion ≈ $30.80 Million |
₩124.73 Billion ≈ $84.53 Million |
+3.16pp |
| 2015-12-31 | 33.28% | ₩38.98 Billion ≈ $26.41 Million |
₩117.13 Billion ≈ $79.37 Million |
+26.11pp |
| 2014-12-31 | 7.17% | ₩6.25 Billion ≈ $4.23 Million |
₩87.17 Billion ≈ $59.07 Million |
+0.16pp |
| 2013-12-31 | 7.01% | ₩6.86 Billion ≈ $4.65 Million |
₩97.85 Billion ≈ $66.31 Million |
-12.27pp |
| 2012-12-31 | 19.27% | ₩23.95 Billion ≈ $16.23 Million |
₩124.27 Billion ≈ $84.22 Million |
+11.34pp |
| 2011-12-31 | 7.93% | ₩8.36 Billion ≈ $5.67 Million |
₩105.46 Billion ≈ $71.47 Million |
-- |
About Hanall Biopharma
Hanall Biopharma Co., Ltd., a pharmaceutical company, manufactures and sells pharmaceutical products in South Korea and internationally. The company offers prescription drugs and over-the-counter products for the treatment of diarrhea, prostatic hyperplasia, androgenetic alopecia, chronic renal failure, hypoparathyroidism, vitamin D-resistant rickets, osteomalacia, osteoporosis, prostate cancer, … Read more